<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C36EE55B-5F90-4CC8-8133-9C6576DB6A0D"><gtr:id>C36EE55B-5F90-4CC8-8133-9C6576DB6A0D</gtr:id><gtr:name>Senexis Ltd Cambridge</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/39F6E0CC-F302-4D7C-8B64-E8E4027CEE09"><gtr:id>39F6E0CC-F302-4D7C-8B64-E8E4027CEE09</gtr:id><gtr:name>Rostock University</gtr:name><gtr:address><gtr:line1>Albert-Einstein-Str.2</gtr:line1><gtr:line4>D-18051 Rostock</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:department>Medical Research Council</gtr:department><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C36EE55B-5F90-4CC8-8133-9C6576DB6A0D"><gtr:id>C36EE55B-5F90-4CC8-8133-9C6576DB6A0D</gtr:id><gtr:name>Senexis Ltd Cambridge</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/39F6E0CC-F302-4D7C-8B64-E8E4027CEE09"><gtr:id>39F6E0CC-F302-4D7C-8B64-E8E4027CEE09</gtr:id><gtr:name>Rostock University</gtr:name><gtr:address><gtr:line1>Albert-Einstein-Str.2</gtr:line1><gtr:line4>D-18051 Rostock</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CCCCCB82-55DE-4C4E-BBA2-CA7683EB7CA0"><gtr:id>CCCCCB82-55DE-4C4E-BBA2-CA7683EB7CA0</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Barry</gtr:otherNames><gtr:surname>Sattelle</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0B97844B-F6EA-406E-AE36-89971C1C2DBC"><gtr:id>0B97844B-F6EA-406E-AE36-89971C1C2DBC</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Buckingham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/398CDC3B-CC6B-4503-A2F7-39F63C97694F"><gtr:id>398CDC3B-CC6B-4503-A2F7-39F63C97694F</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Ian</gtr:otherNames><gtr:surname>Scopes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/002FC006-2518-458A-AB1F-FF4586FFE8D7"><gtr:id>002FC006-2518-458A-AB1F-FF4586FFE8D7</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Hanna</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A3DB76B2-176A-4ED2-A07B-E587E9D577C6"><gtr:id>A3DB76B2-176A-4ED2-A07B-E587E9D577C6</gtr:id><gtr:firstName>Linda</gtr:firstName><gtr:surname>Greensmith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801760"><gtr:id>3D7A0D6A-9772-41ED-88D3-346C720BFAB4</gtr:id><gtr:title>New Therapeutic approaches to Inclusion Body Myositis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801760</gtr:grantReference><gtr:abstractText>Inclusion Body Mysositis is the most common acquired muscle disease affecting people over 50 years old and is characterized by muscle weakness and degeneration, as well as chronic muscle inflammation. IBM affects 35 people in every million in the population over the age of 50 years. There is currently no effective treatment.

Developing new drugs for degenerative diseases is made much quicker when cell-based or invertebrate models are available. We have a simple nematode worm that has been genetically altered to mimic IBM. The diseased worms are noticeably less active than unaffected worms, which allows them to be distinguished from healthy ones. We already have a rapid working assay in place for this study and will develop an upscaled method for screening the actions of large numbers of compounds on these modified worms, to identify those which reverse the effects of IBM. This will not only provide new leads for drugs for treating IBM, but will also provide a method for screening large numbers of compounds that can be used in this and other applications. The most promising compounds will be tested on a human muscle cell line.</gtr:abstractText><gtr:technicalSummary>Inclusion Body Mysositis is the most common acquired muscle disease affecting people over 50 years old and is characterized by muscle weakness and degeneration, as well as chronic muscle inflammation. IBM affects 35 people in every million in the population over the age of 50 years. There is currently no effective treatment. We will exploit an existing invertebrate model of IBM to screen a large library of novel compounds to identify possible new routes to therapy.

Oxford and UCL will collaborate with Senexis to develop models for the rapid assay of potential treatments for IBM. Oxford has a Caenorhabditis elegans model of IBM in which beta-amyloid is overexpressed in the muscle under the control of a heat-shock promoter. Induction of Abeta expression results in accumulation of amyloid deposits in the somatic muscles accompanied with paralysis and shortened lifespan. Oxford will develop a high-throughput assay for compounds that rescue the Abeta-induced paralysis. This will ensure that any increase in compound numbers can be accommodated. The results will be validated using an established human myoblast cell line.

UCL has expertise in cell line models of amyloid disease which will be used in parallel with the C. elegans models to screen Senexis compounds and to validate their action on a human model.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>91149</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rostock</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Neuroembryonic Research Laboratory Rostock</gtr:department><gtr:description>Rostock collaboration</gtr:description><gtr:id>56B19FBB-E4A0-4566-97F7-1C4FD2BD3EAA</gtr:id><gtr:impact>J Comp Neurol 497, 808-816. PMID:16786553
Briese et al. Human Mol genet 200918:97-104.</gtr:impact><gtr:partnerContribution>Access to unique research materials</gtr:partnerContribution><gtr:piContribution>antibody localisation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Senexis Ltd Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Senexis collaboration on inhibitors of amyloid aggregation</gtr:description><gtr:id>7114A9CD-FD4F-40ED-B73F-5BCDCD68B185</gtr:id><gtr:impact>Output was a successful grant bid (output of grant described in G0801760)</gtr:impact><gtr:partnerContribution>Novel chemistry</gtr:partnerContribution><gtr:piContribution>We developed the use of a C. elegans model for screening drugs that inhibit amyloid aggregation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Proof of concept trial</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>61C03C98-B9C1-4C4D-950E-AA669A44894B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1543444</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Project grant: A randomised controlled trial of efficacy of heat shock protein upregulation in IBM</gtr:description><gtr:fundingOrg>Food and Drug Administration (FDA)</gtr:fundingOrg><gtr:id>817F5C81-6AB8-420C-89F9-48CC2C27926D</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Drugs known to reduce amyloid aggregation were shown to ameliorate amyloid induced paralysis in a C. elegans transgenic model expressing human beta amyloid protein. This validated assay can be used to explore novel chemistry.</gtr:description><gtr:id>41D8602E-1051-4BB5-A2BD-071BB7F9CA65</gtr:id><gtr:impact>A paper is in press (Feb 2010 publication date) in Disease Models and Mechanisms describing this work. The assay is accelerating drug screening.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Validated assay for exploring drugs for IBM therapy</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F8377384-78E1-47B4-A0ED-EEAB753CEF46"><gtr:id>F8377384-78E1-47B4-A0ED-EEAB753CEF46</gtr:id><gtr:title>Functional genomics: applying calcium imaging and RNA interference to Drosophila cell lines to identify new roles for gene products.</gtr:title><gtr:parentPublicationTitle>Invertebrate neuroscience : IN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/020a06f84500a7f5e3fc661ff2d82a3a"><gtr:id>020a06f84500a7f5e3fc661ff2d82a3a</gtr:id><gtr:otherNames>Buckingham SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1354-2516</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/353D6304-D8DF-4527-BCBA-65BD02D238F5"><gtr:id>353D6304-D8DF-4527-BCBA-65BD02D238F5</gtr:id><gtr:title>Strategies for automated analysis of C. elegans locomotion.</gtr:title><gtr:parentPublicationTitle>Invertebrate neuroscience : IN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/020a06f84500a7f5e3fc661ff2d82a3a"><gtr:id>020a06f84500a7f5e3fc661ff2d82a3a</gtr:id><gtr:otherNames>Buckingham SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1354-2516</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/42C3D8C0-94F6-42A0-AB6D-65F5390C8FBD"><gtr:id>42C3D8C0-94F6-42A0-AB6D-65F5390C8FBD</gtr:id><gtr:title>Gene expression profiling studies on Caenorhabditis elegans dystrophin mutants dys-1(cx-35) and dys-1(cx18).</gtr:title><gtr:parentPublicationTitle>Genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aeaf036b5660e23ffc91057604ee4cf3"><gtr:id>aeaf036b5660e23ffc91057604ee4cf3</gtr:id><gtr:otherNames>Towers PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0888-7543</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E240D6C-0842-40E6-BAF6-7BB9700EB199"><gtr:id>8E240D6C-0842-40E6-BAF6-7BB9700EB199</gtr:id><gtr:title>C. elegans models of neuromuscular diseases expedite translational research</gtr:title><gtr:parentPublicationTitle>Translational Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7fb46e850eb3256a53dc7abec1148706"><gtr:id>7fb46e850eb3256a53dc7abec1148706</gtr:id><gtr:otherNames>Sleigh J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/190313D3-E5BC-45FB-9ED8-FA01C9A11C45"><gtr:id>190313D3-E5BC-45FB-9ED8-FA01C9A11C45</gtr:id><gtr:title>Fast, automated measurement of nematode swimming (thrashing) without morphometry.</gtr:title><gtr:parentPublicationTitle>BMC neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/020a06f84500a7f5e3fc661ff2d82a3a"><gtr:id>020a06f84500a7f5e3fc661ff2d82a3a</gtr:id><gtr:otherNames>Buckingham SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2202</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801760</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>